Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature.
CSC
anticancer
cancer
cancer stem cells
chemoresistance
mebendazole
radioresistance
repurposing
stemness
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Aug 2019
31 Aug 2019
Historique:
received:
29
07
2019
revised:
27
08
2019
accepted:
28
08
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
5
9
2019
Statut:
epublish
Résumé
Anticancer treatment efficacy is limited by the development of refractory tumor cells characterized by increased expression and activity of mechanisms promoting survival, proliferation, and metastatic spread. The present review summarizes the current literature regarding the use of the anthelmintic mebendazole (MBZ) as a repurposed drug in oncology with a focus on cells resistant to approved therapies, including so called "cancer stem cells". Mebendazole meets many of the characteristics desirable for a repurposed drug: good and proven toxicity profile, pharmacokinetics allowing to reach therapeutic concentrations at disease site, ease of administration and low price. Several in vitro studies suggest that MBZ inhibits a wide range of factors involved in tumor progression such as tubulin polymerization, angiogenesis, pro-survival pathways, matrix metalloproteinases, and multi-drug resistance protein transporters. Mebendazole not only exhibits direct cytotoxic activity, but also synergizes with ionizing radiations and different chemotherapeutic agents and stimulates antitumoral immune response. In vivo, MBZ treatment as a single agent or in combination with chemotherapy led to the reduction or complete arrest of tumor growth, marked decrease of metastatic spread, and improvement of survival. Further investigations are warranted to confirm the clinical anti-neoplastic activity of MBZ and its safety in combination with other drugs in a clinical setting.
Identifiants
pubmed: 31480477
pii: cancers11091284
doi: 10.3390/cancers11091284
pmc: PMC6769799
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Comb Chem High Throughput Screen. 2015;18(8):784-94
pubmed: 26234515
J Neurooncol. 2018 Dec;140(3):529-538
pubmed: 30414098
Br J Clin Pharmacol. 1985 Jan;19(1):79-86
pubmed: 3978023
Mol Cancer Ther. 2015 Jan;14(1):3-13
pubmed: 25376612
Oncogene. 2014 Sep 4;33(36):4451-63
pubmed: 24096485
Pharmacol Ther. 2016 Apr;160:145-58
pubmed: 26899500
Br J Cancer. 2017 Nov 21;117(11):1583-1591
pubmed: 29065107
Neurosurg Clin N Am. 2016 Apr;27(2):239-47
pubmed: 27012388
Ecancermedicalscience. 2014 Jul 10;8:443
pubmed: 25075217
Clin Cancer Res. 2015 Aug 1;21(15):3462-3470
pubmed: 25862759
Int J Surg. 2008 Dec;6(6):448-51
pubmed: 18819855
Cancer Chemother Pharmacol. 2010 Feb;65(3):597-605
pubmed: 19904538
Mol Cancer Ther. 2002 Nov;1(13):1201-9
pubmed: 12479701
J Cancer Res Ther Oncol. 2014 Apr 9;2(1):null
pubmed: 25844392
Cancer Chemother Pharmacol. 2008 Apr;61(5):809-17
pubmed: 17581752
Eur J Clin Pharmacol. 1982;22(2):161-9
pubmed: 7094986
Oral Oncol. 2016 Jul;58:59-70
pubmed: 27215705
Leukemia. 2018 Apr;32(4):882-889
pubmed: 29089643
Nat Rev Cancer. 2012 Dec;12(12):818-34
pubmed: 23175120
Ecancermedicalscience. 2014 Jul 10;8:442
pubmed: 25075216
J Invest Dermatol. 2010 Sep;130(9):2250-8
pubmed: 20520630
Mol Cancer Res. 2008 Aug;6(8):1308-15
pubmed: 18667591
Nat Rev Clin Oncol. 2015 Dec;12(12):732-42
pubmed: 26483297
Endocr Pract. 2011 May-Jun;17(3):e59-62
pubmed: 21454232
Bull World Health Organ. 1996;74(3):231-42
pubmed: 8789923
Acta Oncol. 2014 Mar;53(3):427-8
pubmed: 24160353
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1571-6
pubmed: 25605897
J Cancer Res Clin Oncol. 2013 Dec;139(12):2133-40
pubmed: 24135855
Toxicol In Vitro. 2019 Oct;60:305-312
pubmed: 31207347
Breast. 2016 Dec;30:92-100
pubmed: 27668856
Oncotarget. 2017 Jul 6;8(35):59950-59964
pubmed: 28938696
Toxicol In Vitro. 2015 Dec;29(8):2038-44
pubmed: 26315676
Toxicol In Vitro. 2017 Sep;43:87-91
pubmed: 28606429
Eur J Clin Pharmacol. 1980 May;17(5):375-8
pubmed: 7418715
Biomol Ther (Seoul). 2019 Jan 31;27(1):117-125
pubmed: 30642153
J Med Chem. 2012 Aug 9;55(15):6832-48
pubmed: 22780961
Sci Rep. 2016 Sep 21;6:33534
pubmed: 27650168
Int J Clin Pharmacol Ther Toxicol. 1985 Dec;23(12):633-41
pubmed: 4093204
Ann Trop Med Parasitol. 1992 Feb;86(1):59-66
pubmed: 1616396
Cancer Sci. 2017 May;108(5):818-823
pubmed: 28208209
Cancer Invest. 2019;37(1):46-65
pubmed: 30599775
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Oncotarget. 2017 Feb 21;8(8):12576-12595
pubmed: 28157711
Nat Rev Drug Discov. 2012 Mar 01;11(3):191-200
pubmed: 22378269
Cell Stem Cell. 2019 Jan 3;24(1):25-40
pubmed: 30595497
Nat Med. 2013 Nov;19(11):1410-22
pubmed: 24202394
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):195-207
pubmed: 30196056
Invest New Drugs. 2018 Apr;36(2):323-331
pubmed: 28852916
Oncotarget. 2016 Oct 18;7(42):68571-68584
pubmed: 27612418
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
Arch Dis Child. 1991 Apr;66(4):532-3
pubmed: 2031617
J Photochem Photobiol B. 2016 Feb;155:1-6
pubmed: 26709667
Immunopharmacol Immunotoxicol. 2017 Aug;39(4):199-210
pubmed: 28472897
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Br J Clin Pharmacol. 1982 Sep;14(3):453-5
pubmed: 7126419
Clin Cancer Res. 2002 Sep;8(9):2963-9
pubmed: 12231542
Anticancer Drugs. 2013 Feb;24(2):181-8
pubmed: 23059386
Oncotarget. 2018 Jul 20;9(56):30805-30813
pubmed: 30112108
Eur J Clin Pharmacol. 2009 Oct;65(10):999-1006
pubmed: 19562329
Neuro Oncol. 2015 Apr;17(4):545-54
pubmed: 25253417
Mol Med. 2017 Apr;23:50-56
pubmed: 28386621
Oncotarget. 2017 Feb 21;8(8):12968-12982
pubmed: 28099902
Breast. 2017 Aug;34 Suppl 1:S27-S30
pubmed: 28668293
Cancers (Basel). 2018 Nov 28;10(12):null
pubmed: 30487436
Nat Rev Cancer. 2012 Jun 14;12(7):487-93
pubmed: 22695393
Br J Pharmacol. 2018 Jan;175(2):168-180
pubmed: 28369768
BMC Res Notes. 2019 Apr 22;12(1):234
pubmed: 31010428
Front Pharmacol. 2016 Mar 14;7:57
pubmed: 27014071
P T. 2017 Aug;42(8):514-521
pubmed: 28781505
Neuro Oncol. 2011 Sep;13(9):974-82
pubmed: 21764822
Eur J Cancer. 2013 Nov;49(16):3387-95
pubmed: 23880474
Onco Targets Ther. 2017 Nov 24;10:5633-5642
pubmed: 29200877
Nat Rev Drug Discov. 2009 Nov;8(11):892-909
pubmed: 19876042
Acta Trop. 2003 May;86(2-3):141-59
pubmed: 12745134
Chem Biol Interact. 2018 Sep 25;293:124-132
pubmed: 30075109
Am J Trop Med Hyg. 1986 Mar;35(2):350-1
pubmed: 3953948
Expert Opin Drug Metab Toxicol. 2015 May;11(5):795-809
pubmed: 25836015
J Clin Gastroenterol. 1999 Jan;28(1):44-5
pubmed: 9916665
Clin Transl Med. 2018 Mar 1;7(1):11
pubmed: 29541939